Key result
The crosstalk between fat homeostasis and liver regional immunity plays a crucial role in NAFLD progression, suggesting immunotherapy as a potential future treatment.
Why the study?
NAFLD is a growing global health threat, and there is currently no effective treatment.
This review highlights the role of liver regional immunity and fat homeostasis in NAFLD progression, proposing immunotherapy as a potential therapeutic avenue.
Answers are grounded in this paper and cite their sources.
Should not yet change NAFLD practice; leaves open immunotherapy trials targeting fat-immune crosstalk.
The liver is well known as the center of glucose and lipid metabolism in the human body. It also functions as an immune organ. Previous studies have suggested that liver nonparenchymal cells are crucial in the progression of NAFLD. In recent years, NAFLD’s threat to human health has been becoming a global issue. And by far, there is no effective treatment for NAFLD. Liver nonparenchymal cells are stimulated by lipid antigens, adipokines, or other factors, and secreted immune factors can alter the expression of key proteins such as SREBP-1c, ChREBP, and PPARγ to regulate lipid metabolism, thus affecting the pathological process of NAFLD. Interestingly, some ncRNAs (including miRNAs and lncRNAs) participate in the pathological process of NAFLD by changing body fat homeostasis. And even some ncRNAs could regulate the activity of HSCs, thereby affecting the progression of inflammation and fibrosis in the course of NAFLD. In conclusion, immunotherapy could be an effective way to treat NAFLD.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2019) conducted a review in NAFLD. The crosstalk between fat homeostasis and liver regional immunity plays a crucial role in NAFLD progression, suggesting immunotherapy as a potential future treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: